Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01616485 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo
A Phase 1 study, sponsored by VIVUS.
- Completed
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
NCT01616485 is a Phase 1 study that has completed, run by VIVUS. The registered enrollment target is 106 participants.
The verdict
NCT01616485, a Phase 1 study, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the hemodynamic response to a sublingual dose of glyceryl trinitrate in subjects receiving oral TA-1790, sildenafil citrate, and placebo.
Interventions
- DRUG Placebo
- DRUG TA-1790
- DRUG Sildenafil citrate
- DRUG Nitrostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2004-03 |
| Est. Completion | 2004-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01616485
The ClinicalTrials.gov registry entry for NCT01616485 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01616485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01616485 about?
NCT01616485 is a clinical study titled "Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo". The objective of this study is to evaluate the hemodynamic response to a sublingual dose of glyceryl trinitrate in subjects receiving oral TA-1790, sildenafil citrate, and placebo.
What is the current status of trial NCT01616485?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2004-03. Estimated completion is 2004-05.
What interventions are being tested in trial NCT01616485?
The interventions under investigation include: Placebo (DRUG), TA-1790 (DRUG), Sildenafil citrate (DRUG), Nitrostat (DRUG).
Who is sponsoring clinical trial NCT01616485?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.